140 related articles for article (PubMed ID: 28429103)
21. Immunophenotype Anomalies Predict the Development of Autoimmune Cytopenia in 22q11.2 Deletion Syndrome.
Montin D; Marolda A; Licciardi F; Robasto F; Di Cesare S; Ricotti E; Ferro F; Scaioli G; Giancotta C; Amodio D; Conti F; Giardino G; Leonardi L; Ricci S; Volpi S; Baselli LA; Azzari C; Bossi G; Consolini R; Dellepiane RM; Duse M; Gattorno M; Martire B; Putti MC; Soresina A; Plebani A; Ramenghi U; Martino S; Pignata C; Cancrini C
J Allergy Clin Immunol Pract; 2019; 7(7):2369-2376. PubMed ID: 30922987
[TBL] [Abstract][Full Text] [Related]
22. Risk factors of clinical dysimmune manifestations in a cohort of 86 children with 22q11.2 deletion syndrome: A retrospective study in France.
Mahé P; Nagot N; Portales P; Lozano C; Vincent T; Sarda P; Perez MJ; Amedro P; Marin G; Jeziorski E
Am J Med Genet A; 2019 Nov; 179(11):2207-2213. PubMed ID: 31471951
[TBL] [Abstract][Full Text] [Related]
23. Immunologic defects in 22q11.2 deletion syndrome.
McLean-Tooke A; Barge D; Spickett GP; Gennery AR
J Allergy Clin Immunol; 2008 Aug; 122(2):362-7, 367.e1-4. PubMed ID: 18485468
[TBL] [Abstract][Full Text] [Related]
24. CATCH 22: deletion of locus 22q11 in velocardiofacial syndrome, DiGeorge anomaly, and nonsyndromic conotruncal defects.
Hou JW; Wang JK; Tsai WY; Chou CC; Wang TR
J Formos Med Assoc; 1997 Jun; 96(6):419-23. PubMed ID: 9216164
[TBL] [Abstract][Full Text] [Related]
25. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome).
Finocchi A; Di Cesare S; Romiti ML; Capponi C; Rossi P; Carsetti R; Cancrini C
Pediatr Allergy Immunol; 2006 Aug; 17(5):382-8. PubMed ID: 16846458
[TBL] [Abstract][Full Text] [Related]
26. Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome.
Aresvik DM; Øverland T; Lima K; Pettersen RD; Abrahamsen TG
J Clin Immunol; 2019 Jan; 39(1):65-74. PubMed ID: 30569262
[TBL] [Abstract][Full Text] [Related]
27. [22q11.2 deletion syndrome: importance of clinical evaluation and FISH analysis].
Koshiyama DB; Rosa RF; Zen PR; Pereira VL; Graziadio C; Cóser VM; Ricachinevsky CP; Varella-Garcia M; Paskulin GA
Rev Assoc Med Bras (1992); 2009; 55(4):442-6. PubMed ID: 19750312
[TBL] [Abstract][Full Text] [Related]
28. Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome.
Dar N; Gothelf D; Korn D; Frisch A; Weizman A; Michaelovsky E; Carmel M; Yeshayahu Y; Dubnov-Raz G; Pessach IM; Simon AJ; Lev A; Somech R
Pediatr Res; 2015 Apr; 77(4):579-85. PubMed ID: 25580739
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Severity of T Cell Lymphopenia and Immune Dysregulation in Patients with DiGeorge Syndrome (22q11.2 Deletions and/or Related TBX1 Mutations): a USIDNET Study.
Deshpande DR; Demirdag YY; Marsh RA; Sullivan KE; Orange JS;
J Clin Immunol; 2021 Jan; 41(1):29-37. PubMed ID: 32949294
[TBL] [Abstract][Full Text] [Related]
30. Accelerated Maturation, Exhaustion, and Senescence of T cells in 22q11.2 Deletion Syndrome.
Smetanova J; Milota T; Rataj M; Bloomfield M; Sediva A; Klocperk A
J Clin Immunol; 2022 Feb; 42(2):274-285. PubMed ID: 34716533
[TBL] [Abstract][Full Text] [Related]
31. Would mean platelet volume/platelet count ratio be used as a novel formula to predict 22q11.2 deletion syndrome?
Gokturk B; Guner SN; Kara R; Kirac M; Keles S; Artac H; Zamani AG; Yildirim MS; Reisli I
Asian Pac J Allergy Immunol; 2016 Jun; 34(2):166-73. PubMed ID: 27007839
[TBL] [Abstract][Full Text] [Related]
32. Immune system defects in DiGeorge syndrome and association with clinical course.
Nain E; Kiykim A; Ogulur I; Kasap N; Karakoc-Aydiner E; Ozen A; Baris S
Scand J Immunol; 2019 Nov; 90(5):e12809. PubMed ID: 31322747
[TBL] [Abstract][Full Text] [Related]
33. Incidence and significance of 22q11.2 hemizygosity in patients with interrupted aortic arch.
Rauch A; Hofbeck M; Leipold G; Klinge J; Trautmann U; Kirsch M; Singer H; Pfeiffer RA
Am J Med Genet; 1998 Jul; 78(4):322-31. PubMed ID: 9714433
[TBL] [Abstract][Full Text] [Related]
34. [Study on clinical features and fluorescence in situ hybridization detections of 22q11 microdeletion syndrome].
Qin YF; Yang JB; Xie CH; Shao J; Zhao ZY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Jun; 24(3):284-7. PubMed ID: 17557238
[TBL] [Abstract][Full Text] [Related]
35. Congenital cytomegalovirus infection in a preterm infant with 22q11.2 deletion syndrome and immunological abnormalities.
Shitara Y; Toyofuku E; Doi H; Mukai T; Kashima K; Kakiuchi S; Kato M; Takahashi N
Nagoya J Med Sci; 2024 Feb; 86(1):149-154. PubMed ID: 38505727
[TBL] [Abstract][Full Text] [Related]
36. Molecular cytogenetic analysis of a series of 23 DiGeorge syndrome patients by fluorescence in situ hybridization.
Demczuk S; Desmaze C; Aikem M; Prieur M; Ledeist F; Sanson M; Rouleau G; Thomas G; Aurias A
Ann Genet; 1994; 37(2):60-5. PubMed ID: 7985979
[TBL] [Abstract][Full Text] [Related]
37. Association between hypoparathyroidism and defective T cell immunity in 22q11.2 deletion syndrome.
Herwadkar A; Gennery AR; Moran AS; Haeney MR; Arkwright PD
J Clin Pathol; 2010 Feb; 63(2):151-5. PubMed ID: 20154038
[TBL] [Abstract][Full Text] [Related]
38. Chromatin Modifications in 22q11.2 Deletion Syndrome.
Zhang Z; Shi L; Song L; Maurer K; Zhao X; Zackai EH; McGinn DE; Crowley TB; McGinn DMM; Sullivan KE
J Clin Immunol; 2021 Nov; 41(8):1853-1864. PubMed ID: 34435264
[TBL] [Abstract][Full Text] [Related]
39. [Genetic and clinical characteristics of 22q11.2 deletion syndrome].
Kozlova IuO; Zabnenkova VV; Shilova NV; Min'zhenkova ME; Antonenko VG; Kotlukova NP; Simonova LV; Kazanceva IA; Levchenko EG; Bombardirova TD; Zolotukhina TV; Poliakov AV
Genetika; 2014 May; 50(5):602-10. PubMed ID: 25715476
[TBL] [Abstract][Full Text] [Related]
40. Deletion 22q11.2 syndrome--implications for the intensive care physician.
Jatana V; Gillis J; Webster BH; Adès LC
Pediatr Crit Care Med; 2007 Sep; 8(5):459-63; quiz 464. PubMed ID: 17873780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
